Mediar Therapeutics

Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar’s midphase prospect

Mediar prioritizes an inclusive culture that supports employees’ authentic selves and aims for impartial, fair practices and programs with equal possible outcomes.

The company aims to pioneer therapies for fibrotic diseases to make a meaningful impact and provide hope for patients.

Mediar Therapeutics, Inc. is located at 201 Brookline Ave, Suite 1002 (10th floor), Boston, MA 02215. The company lists info@mediartx.com as its contact email.

Mediar says myofibroblasts deposit collagen and extracellular matrix and maintain a pro-fibrotic micro-environment. It is running clinical studies in fibrosing diseases and aims to slow or possibly reverse fibrosis by deactivating myofibroblasts.

Mediar Therapeutics, Inc.’s privacy policy explains how it collects, uses, and shares personal and other information from visitors to its website, related services, and other online properties.

Mediar Therapeutics finishes early enrollment of 168 patients in its Phase 2 WISPer trial testing **MTX-463** for **idiopathic pulmonary fibrosis (IPF)** across over 70 clinical sites. The trial partners with **Eli Lilly** to evaluate the drug’s safety and efficacy in treating this progressive lung disease.

Oct 2026sofinnovapartners.comNews article

Mediar Therapeutics begins dosing patients in the first cohorts of its Phase 1 clinical trial for **MTX-439**, a first-in-class antibody targeting **SMOC2** to treat fibrosis linked to chronic kidney disease (CKD). The company’s pipeline now includes three novel anti-fibrotic programs entering clinical development. Mediar also announces additions to its Clinical Advisory Board to support the trial’s progression.

Jun 2026BioSpaceNews article

Mediar Therapeutics secures a $76 million Series B funding round to develop anti-fibrotic therapies. The round is co-led by Amplitude Ventures and ICG, targeting diseases including systemic sclerosis (SSc), idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD). The capital will accelerate the company’s pipeline of treatments addressing fibrosis-related conditions.

Jan 2026sofinnovapartners.comNews article

Eli Lilly acquires global rights to Mediar Therapeutics’ anti-WISP1 antibody **MTX-463**, a phase 2 candidate for treating **idiopathic pulmonary fibrosis (IPF)**. The deal includes a **$99 million upfront and near-term payment**, with up to **$687 million in milestones**. Lilly targets the IPF market, where WISP1 has been linked to disease progression.

Jan 2025Mediar TherapeuticsNews article